Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 5 30 versus LARIN FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 5 30 versus LARIN FE 1 20.
LARIN 1.5/30 vs LARIN FE 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
None Documented
None Documented
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive